Dosage adjustment may be necessary.

No pharmaceutical opinion available for this interaction.


Rifapentin can induce the metabolism (CYP 3A4) and decrease the plasma concentration of Dolutegravir.


Pharmacodynamic effects

Possible decrease of clinical efficacy and risk of possible development of resistance to antiretroviral class.


Co-administration with rifapentine once daily (1HP) : Increase dolutegravir dose to 50 mg BID for Tivicay and administer an additional 50 mg dose of dolutegravir 12 hours after Triumeq or Dovato.

Co-administration with rifapentine once weekly (3HP) : No dose adjustment is necessary.

Monitor for clinical efficacy.

Avoid combination in patients with resistance to integrase inhibitors.

Juluca : Concomitant administration contraindicated.

Alternative solution(s)


Pharmacodynamic effects


Alternative solution(s)

Rifabutin : see dolutegravir + rifabutin.



Dolutegravir plasma level


Viral load HIV

Pharmacokinetic parameters


Rifapentine once daily (1 HP)
Ref #3647 : In this study, 25 HIV-positive patients with indications of latent tuberculosis received rifapentine/isoniazid 600/300 mg QD (1 HP) and dolutegravir 50 mg BID for one month. Dolutegravir concentrations were always higher to those of dolutegravir alone at a standard dose of 50 mg QD. 24 patients had a viral load <50 copies/mL on day 28 (all on day 42). No serious adverse effects have been reported.

Ref #3649 : In this retrospective analysis in PLWH with latent tuberculosis, all patients (44/44) taking 1HP and dolutegravir containing regimen maintained viral loads <200 copies/mL at months 3-6 after the completion of LTBI treatment.

Rifapentine once a week (3 HP)
Ref #3646 : In this study, 60 HIV-positive patients received rifapentine/isoniazid 900/900 mg once weekly QD (3 HP) and dolutegravir 50 mg QD for 3 months. Dolutegravir concentrations decreased by 47% however all but one of the trough values measured during the 12 weeks were above the 90% maximum inhibitory concentration for dolutegravir (300 ng/mL). All patients had an undetectable viral load (<40 copies/mL). No adverse reactions related to rifapentine or isoniazid above grade 3 have been reported.

Ref #3343 : This study was stopped prematurely due to serious toxicities, possibly related to high isoniazid exposure (67-92% higher than expected), observed in 2 of 3 subjects receiving 3 doses of weekly isoniazid/rifapentine (wHP) with once daily dolutegravir. Limited PK data from these subjects showed decreased dolutegravir exposure by 46% and Cmin values by 74% with wHP co-administration. Researchers suggest to avoid co-administration.

Ref #3649 : In this retrospective analysis in PLWH with latent tuberculosis, 96.7% of patients (178/184) taking 3HP and bictegravir containing regimen maintained viral loads <200 copies/mL at months 3-6 after the completion of LTBI treatment.

  • 3647
    Imperial MZ, Luetkemeyer A, Dawson R, Cramer Y, Rosenkranz S et al. DTG PK in people with HIV receiving daily 1HP for latent TB treatment (ACTG A5372). Conference on Retroviruses and Opportunistic Infections (virtual CROI), February 12-16, 2022. Abstract #78.
  • 3646
    Dooley KE, Savic R, Gupte A et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV 2020; 7(6):e401-9.
  • 3343
    Brooks KM, Pau AK, George JM, Alfaro R, Kellogg A et al. Early Termination of a PK Study Between Dolutegravir and Weekly Isoniazid/Rifapentine. CROI 2017, Seattle, WA USA, February 13-16 2017. Abstract #409a.
  • 3441
    Dolutegravir/Rilpivirine (Juluca), ViiV Healthcare ULC, Quebec, Canada, 19 août 2021.
  • 3649
    Lin KY, Sun HY, Yang CJ, Lu PL, Lee NY, et al. Short-course rifapentine-based regimens for latent tuberculosis injection among people living with HIV who received integrase inhibitor-based antiretroviral therapy. IAS 2023 Conference, Brisbane, Australia. July 23-26, 2023. Abstract #3454.